Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Bolt Biotherapeutics (BOLT) Shares Outstanding (Diluted Average) (2021 - 2025)

Bolt Biotherapeutics (BOLT) has disclosed Shares Outstanding (Diluted Average) for 5 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding (Diluted Average) fell 2.06% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, down 2.06% year-over-year, with the annual reading at $1.9 million for FY2025, 2.06% down from the prior year.
  • Shares Outstanding (Diluted Average) hit $1.9 million in Q4 2025 for Bolt Biotherapeutics, down from $1.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $38.3 million in Q1 2025 to a low of $1.9 million in Q4 2025.
  • Historically, Shares Outstanding (Diluted Average) has averaged $25.5 million across 5 years, with a median of $37.2 million in 2021.
  • Biggest five-year swings in Shares Outstanding (Diluted Average): rose 12.54% in 2022 and later tumbled 94.95% in 2024.
  • Year by year, Shares Outstanding (Diluted Average) stood at $33.2 million in 2021, then rose by 12.54% to $37.4 million in 2022, then increased by 1.21% to $37.8 million in 2023, then crashed by 94.95% to $1.9 million in 2024, then fell by 2.06% to $1.9 million in 2025.
  • Business Quant data shows Shares Outstanding (Diluted Average) for BOLT at $1.9 million in Q4 2025, $1.9 million in Q3 2025, and $1.9 million in Q2 2025.